ImmuneOnco Biopharma

[Not Yet Scheduled]
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to development and commercialization of innovative cancer immunotherapy. The company has established several solid platforms harnessing both innate and adaptive immune cells. ImmuneOnco takes the advantage of the engineered and IP-protected SIRP-domain to develop the mAb-Traps that simultaneously targeting CD47 and other tumor targets such as CD20, Her2, PD-L1, and FLT-3. The CD47xCD20-specific mAb-Trap has been approved by NMPA for clinical trials in November of 2019 and will enter into phase I clinical test in the first half of 2020.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
June of 2015
Main Therapeutic Focus:
Lead Product in Development:
CD47xCD20 mAb-Trap
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Founder, Chairman & CEO
ImmuneOnco Biopharma